Clinical Trial Update: Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL [Phase 2]

View source ↗

Summary

Phase 2 open-label randomized trial evaluating the combination of pirtobrutinib and Brexucabtagene Autoleucel in relapsed/refractory mantle cell lymphoma; curre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• Brexucabtagene Autoleucel (brexucabtagene autoleucel)
• Pirtobrutinib (pirtobrutinib)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Mantle Cell Lymphoma | Phase 2 | Status: RECRUITING